ELISA Methodology for Detection of Modified Osteoprotegerin in Clinical Studies

Publisher Website
Google Scholar
Abstract
Osteoprotegerin (OPG), also known as osteoclast inhibitory factor, is a soluble receptor of the tumor necrosis factor receptor superfamily. The protein is secreted as a covalent, disulfide-linked homodimer, which is the predominant extracellular form (1), and is expressed in multiple tissues (1)(2)(3). OPG-mediated pathways might have a role in osteoporosis (3)(4)(5)(6) because estrogen increases OPG gene expression (4)(5). OPG maintains the structure of healthy bone and inhibits osteoclast activation and differentiation (3)(7). In the vascular system, OPG inhibits pathological calcification in the media intima (3). OPG has been proposed for therapy of osteopenic disorders, such as postmenopausal osteoporosis, Paget disease, rheumatoid arthritis, hypercalcemia, and lytic bone metastases (8).

This publication has 17 references indexed in Scilit: